Crystalys Therapeutics
PrivateLast Round
Series B
Jul 22, 2026
Est. Valuation
$280M
Total Funding Raised
$358M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Crystalys Therapeutics is a clinical-stage biopharmaceutical company developing dotinurad, a next-generation URAT1 inhibitor, as a second-line therapy for gout.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Crystalys Therapeutics Comparables
Compare Crystalys Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| LG Chem | 78% | |
| Simcere Pharmaceutical Group | 76% | |
| ApicHope Pharmaceutical Group Co.,Ltd. | 75% | |
Crystalys Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jul 22, 2026 | ||||
| Series A | Sep 30, 2025 |
Key People
Founding team and executive leadership
Crystalys Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Soleus Capital | Series B |
| Conrad Prebys Foundation | Series A |
| Prebys Ventures | Series B |
| Wedbush Healthcare Partners | Series A |
| Perceptive Advisors | Series B, Series A |
| KB Investment | Series B, Series A |
| Lightstone Ventures | Series B, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 26, 2026
Monthly visitors grew 49% MoM.
- Jul 22, 2026
$130M round led by Frazier Life Sciences.
Crystalys Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Crystalys Therapeutics's valuation, stock price, and market status.